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Abstract
Background: The aim of this study was to explore the efficacy and define mechanisms of action of PRIMA-1MET as
a TP53 targeted therapy in soft-tissue sarcoma (STS) cells.
Methods: We investigated effects of PRIMA-1MET on apoptosis, cell cycle, and induction of oxidative stress and
autophagy in a panel of 6 STS cell lines with different TP53 status.
Results: Cell viability reduction by PRIMA-1MET was significantly observed in 5 out of 6 STS cell lines. We found that
PRIMA-1MET was capable to induce cell death not only in STS cells harboring mutated TP53 but also in TP53-null
STS cells demonstrating that PRIMA-1MET can induce cell death independently of TP53 in STS cells. We identified an
important role of reactive oxygen species (ROS), involved in PRIMA-1MET toxicity in STS cells leading to a caspase-
independent cell death. ROS toxicity was associated with autophagy induction or JNK pathway activation which
represented potential mechanisms of cell death induced by PRIMA-1MET in STS.
Conclusions: PRIMA-1MET anti-tumor activity in STS partly results from off-target effects involving ROS toxicity and
do not deserve further development as a TP53-targeted therapy in this setting.
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Background
Well-planned wide surgical excision complemented by
adjuvant radiotherapy in cases of large (>5 cm) and/or
deep tumors is the standard loco-regional treatment for
soft-tissue sarcoma (STS) patients [1, 2]. However, despite
optimal local treatment, 30 to 40 % of patients will de-
velop metastatic disease [3]. Doxorubicin is considered as
the standard first-line therapy for patients with advanced
STS and median overall survival is only 12–18 months
[4]. New therapies are therefore needed in this setting.
TP53 is a transcription factor also called “guardian of
genome”, activated under stress conditions, leading to
apoptosis induction and cell cycle arrest [5]. Our re-
search group has previously shown that the p53 pathway
is commonly dysregulated in STS [6] with mutations
found in more than 50 % of STS with complex genomics
profiles. Mutations affecting TP53 cause misfolded pro-
tein and/or lack of DNA interaction capacity [7], (http://
p53.iarc.fr/) with the result of lack of tumor suppressor
function and more recently discovered an oncogenic
gain function [7]. More than 80 % of the mutation oc-
curs in the DNA-binding domain of the gene preventing
correct transcription activity [7]. Based on its crucial role
in carcinogenesis and the frequent dysregulation of the
p53 pathway in cancer, TP53 represent an appealing tar-
get for mechanism-driven anticancer drug discovery.
Nutlins, which prevent p53 proteasomal degradation
via MDM2 interaction [8] has proven some preclinical
efficacy and is now under early clinical phase develop-
ment. In 2002, Bykov et al. [9] isolated from the low mo-
lecular weight compound library of the National Cancer
Institute, a compound that can restore wild-type func-
tion to mutant p53, called PRIMA-1 for P53 Reactiva-
tion and Induction of Massive Apoptosis. The described
molecular mechanism of action is based on the conver-
sion of PRIMA-1 into compounds that form adducts
with thiols in mutant TP53 allowing transcription
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activation [10]. Demonstration of the in vitro and in vivo
activity of PRIMA-1 or its methylated form, PRIMA-
1MET, in terms of apoptosis induction [11–13] and cell
cycle arrest [12, 13] has been reported in different tumor
models. There is no data regarding the activity of
PRIMA-1MET in STS.
The aim of our study was to obtain preliminary proof
of efficacy of PRIMA-1MET in STS cell lines and to as-
sess its specific mechanism of action regarding TP53.
Methods
Cells
The STS cell lines, IB130 (pleiomorphic liposarcoma/
mutant TP53 exon 8, P278L), IB134 (uterine leiomyosar-
coma/mutant TP53 exon 6, S215R), IB136 (soft-tissue
leiomyosarcoma, null TP53), IB117 (myxofibrosarcoma,
null TP53), IB138 (soft-tissue leiomyosarcoma/mutant
TP53 exon 5, V143M), and IB139 (soft tissue leiomyo-
sarcoma, wild-type TP53) used in this study have been
derived from human surgical specimen of STS in the la-
boratory of Pr. Jean-Michel Coindre and Dr Frédéric
Chibon (Institut Berognié, Bordeaux, France) and after
having obtained patient consent. For all the cell lines,
TP53 status was assessed by Sanger sequencing, array-
comparative genomic hybridization and western blotting
(protocols are available on request). Colon carcinoma
cell lines used were HCT-116 (wild type TP53) and HT-
29 (mutant TP53 exon 8, R273H) purchase from the
NCI (http://discover.nci.nih.gov/cellminer/). All cell lines
were cultured in complete RPMI 1640 (Sigma Life Tech-
nologies, Saint Louis, MO) with 10 % Fetal calf serum,
Penicillin/Streptomycin 1 %, and Normocin 0.2 %.
Reagents
PRIMA-1MET and Staurosporin were purchased from
Santa Cruz Biotechnology INC (Heidelberg, Germany).
PRIMA-1MET was stored at −20 °C and diluted in water.
Chloroquine Diphosphate salt and N-acetyl-L-cysteine were
purchased from Sigma Life Science (Saint Louis, MO).
Cell viability
Three thousand cells were seeded in 96-well plates for
24 hr and treated with a range of increasing concentra-
tions of PRIMA-1MET for 24 hr to 96 hr. Methyl Thiazo-
lyl Tétrazolium (MTT, Sigma Aldrich, St Quentin
Fallavier, France) was applied for 3 hours before being
dissolved in dimethylsufoxyde (final concentration:
0.5 mg/mL). Quantity of produced formazan was mea-
sured by spectrophotometry. Absorbance was measured
at 570 nm with a reference at 630 nm. Analysis was
done by using the KC4 software (Kinetical for Windows
V.3.4) and IC50 was calculated with GraphPad Prism
version 5.00 for Windows (GraphPad Software, La Jolla
California USA, www.graphpad.com).
Fluorescent cell sorting analysis (FACS)
Apoptosis and cell cycle were evaluated using Fluores-
cent Activating Cell Sorting (FACS) analysis. For mito-
chondrial membrane depolarization studies, 3000 cells
were seeded in 96-well plates for 24 hours and treated
with a range of increasing concentrations of PRIMA-
1MET for 72 hours, then incubated for 30 min with
Tetramethylrhodamine Methyl Ester (TMRM). P-
glycoprotein drug efflux pump was blocked using
Verapamil (Sigma-Aldrich, St Quentin Fallavier,
France). For activated caspases 3 and 7 detection,
5.105 cells were seeded in 6-wells plates for 24 hours,
treated with increasing doses of PRIMA-1MET for
72 hours and 96 hours, respectively. Cells were har-
vested and exposed to FLICA 1X as described by
the supplier (FAM-FLICA™ Kit, ImmunoChemistry
Technologies, Bloomington, USA) for 1 hour. For
apopotosis/necrosis assay, 1.106 cells were seeded in
6-wells plates for 72 hours, then treated and exposed
to FITC-Annexin and propidium iodide (PI) according
the manufacturer’s protocol (BD Biosciences, Erembo-
degem, Belgium). This allowed distinguishing annexin
V positive cells in early apoptosis, versus annexin V
and PI positives cells in late apoptosis or necrosis.
For cell cycle analysis, 1.105 cells were seeded in 6-
wells plates and after 24 hours cells were treated with
PRIMA-1MET for 48 hours to 96 hours. Cells were
then fixed and permeabilized in absolute ethanol with
PBS over-night at −20 °C, then rinsed and incubated
with RNase and Propidium Iodide (50 μg/mL) (Sigma
Aldrich, St Quentin Fallavier, France). For ROS pro-
duction assay, 6000 cells were seeded in 96-well
plates for 24 hours and treated with PRIMA-1MET for
96 hours, then incubated for 30 min with 2',7'-
Dichlorofluorescin diacetate (DCFDA) 20 μM (Abcam,
Cambridge, MA, USA). We performed flow cytometry
analysis using FL1 for TMRM, FAM-FLICA, Annexin-
V and DCFDA, whereas FL2 was used for Propidium
iodide. Flow cytometry (FACSCalibur; BD Biosciences,
San Jose, USA) data were analyzed with FlowJo
v.7.6.3. software.
Immunoblot analysis
The physical lysis « Ultimate freeze-thaw lysis for mam-
malian cells » protocol was used for non-phosphorylated
protein extraction [14]. For autophagy and phosphory-
lated protein, Radio-ImmunoPrecipitation Assay (RIPA)
lysis buffer protocol [15] was used. Total proteins (30-
60 μg) were separated by 10 or 12 % SDS-PAGE and
transferred on Polyvinyl Difluoride (PVDF) membrane.
The following antibodies were purchased from Cell
Signaling Technology (Danvers, USA): anti-BAX (1:500),
anti-PUMA (1:1000), anti-JNK (1:1000) and anti-phospho
JNK monoclonal antibodies (1:1000). Anti-GAPDH
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(1:200) and anti-p53 (1:1000) monoclonal antibodies were
purchased from Santa Cruz Biotechnology (Heidelberg,
Germany). The anti-p21 monoclonal antibody (1:33) was
purchased from Calbiochem (San Diego, USA). The anti-
LC3IIB monoclonal antibody (1:1000) was purchased
from Sigma Aldrich (Saint Louis, USA) and the anti-PARP
monoclonal antibody (1:1000) was purchased from Enzo-
LifeSciences (Farmingdale, USA). Secondary antibodies
anti-Mouse IgG and anti-Rabbit IgG (1:5000) were pur-
chased from Ge Healthcare (Buckinghamshire, United
Kingdom). Proteins were detected (Fusion Fx7, Fisher Bio-
block Scientific, Waltham, MA, USA) by using enhanced
chemiluminescent substrate for horseradish peroxidase
(HRP) (Immobilon™ Western, Millipore Corporation).
Each membrane was reused 3 times after desaturation in
glycin (6.6 mol/L) buffer pH = 2 at 56 °C for 30 min.
Semi-quantitative analysis was realized with ImageJ 1.45 s
software (Rasband, W.S., ImageJ, U. S. National Institutes
of Health, Bethesda, Maryland, USA, http://imagej.nih.
gov/ij/, 1997–2014).
Confocal microscopy
Cells were seeded on coverslips and treated with
PRIMA-1MET for 72 hours. Slides were then washed
twice with PBS, fixed in formaldehyde 4 % and incubated
with anti-LC3IIB monoclonal antibody (Sigma Aldrich,
Saint Louis, USA) overnight, and then with a goat anti-
rabbit Alexa fluor 488 antibody (Invitrogen, Paisley,
United Kingdom). Slides were then counterstained by
4,6-diamidino-2-phenylindole (DAPI).
Results
Prima-1MET reduces STS cells viability independently of
p53 status
We observed significant and similar sensitivity in term
of viability reduction in the TP53 mutated (MT) STS cell
lines (IB130, IB134, IB138) and in the TP53 null cell
lines (IB136, IB117) after exposure to PRIMA-1MET for
96 hours (Fig. 1). PRIMA-1MET induced more growth in-
hibition in these cell lines than in the TP53 wild-type
(WT) cell line (IB139). Mutated STS cell lines (IB130,
IB134, IB138) and null cell lines (IB136, IB117) have
equivalent IC50 (approximately 10 μM, Fig. 1), about
twice less than wild type cell lines (IB139). HCT-116
(WT) and HT-29 (MT) cells were equally sensitive to
PRIMA-1MET (approximately 10 μM, data not shown).
Those results indicate that PRIMA-1MET act independently
of p53 in the p53 null cell line and that PRIMA-1MET is
more effective in mutated than wild type STS cell lines.
PRIMA-1MET does not induce apoptosis in STS cell lines
Induction of apoptosis has been largely demonstrated as
key mechanisms of action of PRIMA-1MET [11–13]. By
using caspase 3/7 and Annexin V assays, we found that
PRIMA-1MET does not induce significant apoptosis in
our STS cell lines regardless of TP53 status. There were
no activation of caspases 3 and 7 in mutated or deleted
cell lines and a non-significant induction has only been
found with high doses of PRIMA-1MET in the TP53-wild
type cell line IB139 (Fig. 2a). Moreover, no PARP cleav-
age was observed after exposure to PRIMA-1MET
(Fig. 2b). In addition, by using Annexin V/PI assay, no
apoptosis was detected whatever the TP53 status
(Fig. 2c). However, we found that PRIMA-1MET increased
the percentage of cell death in the three TP53-mutated
and TP53-deleted cell lines compared with the wild-type
cell line (IB139). No accumulation of annexin V positive
cells was identified when treating HCT-116 (WT) and
HT-29 (MT) with PRIMA1-MET (data not shown).
PRIMA-1MET does not induce p53-dependent cell cycle ar-
rest in STS cell lines
One of the putative mechanisms of action of PRIMA-
1MET is restoring p53 functions as a sequence-specific
transcription factor that drives the transactivation of tar-








Fig. 1 Growth suppression effect of PRIMA-1MET. Effect were assessed by MTT using different concentrations in each of the 6 indicated STS cell
lines, with respective IC50 values, n = 3-4, error bars show SEM
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Treatment of STS cells for 24, 48 or 72 hours with
PRIMA-1MET did not result in dose dependent cell cycle
arrest and induction of P21. PRIMA-1MET induced cell
cycle arrest in HCT-116 cells in a dose dependent man-
ner (data not shown). Those results combined with the
lack of apoptosis suggest that PRIMA-1MET effect is
largely p53 independent in STS cells.
PRIMA-1MET-induced STS cells death is associated with a
loss of mitochondrial membrane potential (MMP) and
reactive oxygen species (ROS) toxicity independently of
the p53 status
PRIMA-1MET has been shown to exert its effect in part
via inducing ROS production and therefore promoting
an oxidative environment in tumor cells [10, 16, 17]. We
treated our panel of STS cell lines with PRIMA-1MET
and we quantified ROS levels by using the fluorogenic
dye DCFDA with flow cytometry. As indicated in Fig. 3a,
we observed an induction of ROS by PRIMA1-MET not
related to p53 status. This production of ROS was ac-
companied with a loss of mitochondrial membrane po-
tential (Fig. 3c). Further, we functionally analyzed the
effects of blocking ROS production by N-acetyl cysteine
(NAC) on PRIMA-1MET-induced cell growth suppres-
sion. As shown in Fig. 3b, 2.5 mM NAC treatment could
completely reverse PRIMA-1MET-induced ROS produc-
tion and suppressed PRIMA-1MET anti-tumor effect in
STS cell lines whatever their p53 status. Same results
were found in the two colon carcinoma cell lines (data
not shown).
PRIMA-1MET induces autophagy and activates JNK
pathway in STS cell lines independently of TP53 status
The exact mechanisms involved in ROS-induced cell
death are not fully understood. There are several lines of
evidence indicating that oxidative stress directly induces
Fig. 2 Cell death induced by PRIMA-1MET on STS cell lines. a caspases 3 and 7 activation in cell lines, upper line represent fusion of FLICA
fluorescence in cells non treated (NT) not marked (blue), NT marked (red) and treated by Staurospaurin (orange) at 1 μM (IB134), 5 μM (IB136
and IB139) for up to 72 hr. Lower line represent fusion of FLICA fluorescence in cells NT not marked (blue), NT marked (red) and treated by
Prima-1MET (orange) at 60 μM (IB134) or 80 μM (IB136 and IB139) for up to 72 hr. b Levels of the indicated proteins evaluated by Western blot
analysis after exposure for up to 72 hours to specific defined cell line IC50 PRIMA-1MET doses. c Cell death analyses using FITC annexin-V
and propidium iodide assay. Upper line compare NT condition (red) to PRIMA-1MET at IC50 cell line specific dose (blue) defined by MTT
assay, lower line compare NT (red) to 80 μM of PRIMA-1MET except for IB117 (50 μM) (blue)
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autophagy, as a cell death mechanism. For this reason,
we decided to investigate whether PRIMA-1MET-associ-
ated ROS toxicity was coupled with autophagy induction
in STS cell lines. LC3 is specifically localized to autopha-
gic structures. When autophagy is not activated, LC3 is
localized homogeneously in the cytoplasm, while upon
initiation of autophagy, it associates with the membrane
of autophagosomes. Since increase in LC3-II levels or
GFP-LC3 vesicles can occur not only due to increased
autophagosome synthesis but also due to impaired
autophagosome-lysosome fusion, we assessed LC3-II
levels in the presence of chloroquine, a blocker of LC3-
II degradation. Analysis of LC3-II levels by western blot-
ting and by fluorescence microscopy allowed us to de-
tect PRIMA-1MET -induced autophagy in the two STS
cell lines with TP53 mutation (IB 134 and IB 138) but
not in the other ones (Fig. 4a-b). In colon carcinoma
cells, autophagy was induced irrespective of TP53 status.
ROS-dependent activation of JNK has been identified
as a crucial mechanism of cell death [18]. We found that
PRIMA-1MET induced JNK phosphorylation (p-JNK) in
IB130 and IB139 cell lines but not in IB134, IB136 and
IB138 (Fig. 4c). p-JNK was also induced in HT-29 cells
(data not shown).
Discussion
We report here the first study investigating PRIMA-
1MET activity in STS by using 6 cell lines with different
TP53 status. First, we found that PRIMA-1MET altered
significantly cell viability in 5 out the 6 cell lines, two of
them harboring a homozygous deletion of TP53. This
result suggested a mechanism of action of PRIMA-1MET
at least in part independent of TP53. PRIMA-1MET was
first isolated based on its specific action on TP53 mu-
tated cell lines and its ability to re-induce P53 dependent
pathway [8]. However, several studies have shown that
PRIMA-1MET can induce cell death even in tumor
models with no mutation or deletion of TP53 [11, 19,
20] suggesting TP53-independent mechanisms of action.
Recently, Sobhani et al. show that siRNA knockdown of
P53 did not influence the PRIMA-1MET-induced cell














































































































Fig. 3 PRIMA-1MET induces ROS-associated toxicity and loss of MMP. a ROS production estimated by DCF staining and assessed by flow cytometry, not
treated in red, PRIMA-1MET 30 μM (IB130) and 10 μM (IB136) for 96 h in blue. b ROS implication in PRIMA-1MET growth suppression effects using MTT
assay. Cells were treated for 96 h with range of PRIMA -1MET alone (black) and combined with NAC (2,5 mM) (red). c Loss of MMP by cell line with
TMRM fluorescent assay, n = 3, error bars show SEM
Grellety et al. BMC Cancer  (2015) 15:684 Page 5 of 8
Our results are in perfect agreement with those of Sob-
hani et al. [21] and confirm that PRIMA-1MET might in-
volve more complex mechanisms than those originally
described [10] not restricted to a P53 transcriptional re-
lated activity [22].
The second striking result was that PRIMA-1MET did
not induce significant caspase-dependent-apoptosis in
STS. Indeed, contrary to that observed in other tumor
models [13, 22, 23], we did not found any caspase-3 acti-
vation when STS cells were treated with PRIMA-1MET.
Fig. 4 Autophagy and JNK phosphorylation induced by PRIMA-1MET. a Western blot and quantification of LC3II in each cell line after 72 hr of
PRIMA-1MET. Chloroquine (C) was used at 20 μM, NT: Not Treated, P: PRIMA-1MET, C + P: Chloroquine and Prima-1MET. b IB 134 and IB 138 cells
were treated and fixed for immunostaining with an antibody against LC3. Representative images from two independent experiments are shown.
c JNK pathway activation assessed by western blot after 96 hr of PRIMA-1MET exposure. For all these assays PRIMA-1MET doses correspond to previously
found doses responsive for loss of MMP in 50 % of treated cells assessed by TMRM assays; 30 μM for IB130 and IB134, 25 μM for IB138 and IB136 and
50 μM for IB139
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It was therefore apparent that the PRIMA-1MET-induced
cell death in STS was following a caspase-independent
pathway.
Oxidative stress is a common form of cellular stress
and refers to an imbalance of the production and clear-
ance of cellular oxidants resulting in high concentration
of ROS and oxidative damage. Due to their high reactive
potential in reducing-oxidizing reactions, ROS can
oxidize lipids, proteins, and nucleic acids, which in turn
compromise the normal cellular functions of these mac-
romolecules leading to growth arrest, cell senescence,
and even cell death [24]. Because PRIMA-1MET was re-
ported to induce ROS [10, 16, 17], we assessed endogen-
ous ROS production, in our panel of STS cell lines.
Indeed, we found an increase of ROS production in STS
cells treated with PRIMA-1MET, irrespective of the pres-
ence of TP53 and this increase was inhibited by NAC.
The addition of NAC counteracted cell growth inhib-
ition induced by PRIMA-1MET in our STS cell lines.
Altogether, these results indicate that ROS induction
play a crucial role in PRIMA-1MET-induced cell death in
STS as reported in other tumor models [16, 17].
Mechanisms involved in cell death resulting from ROS
induction are not fully elucidated yet. However, in vitro
studies from mammalian cells suggested that ROS regu-
late autophagy in various cell lines as exogenous oxida-
tive stressors induce autophagy [25]. By assessing LC3-II
levels, we showed here that treatment with PRIMA-
1MET induced autophagy in STS cells. We observed this
effect in two STS cell lines with mutated TP53 and in
the wild-type and the mutated colon carcinoma cell
lines. This suggests that induction of autophagy by
PRIMA-1MET is at least in part independent of the mu-
tational status of TP53. Our results are in agreement
with those reported by Russo et al. [26] indicating that
PRIMA-1MET can trigger autophagy in cancer cells re-
gardless of the presence of TP53 and identified autoph-
agy as a potential crucial pathway leading to STS cell
death induced by PRIMA-1MET. Since relation between
autophagy and cell death is still controversial [27], this
will require further investigation.
The JNK pathway is a well-conserved mitogen-
activated protein kinase (MAPK). JNK was first identi-
fied as a stress-activated protein kinase (SAPK) that re-
sponds to various stresses in mammalian cells [28]. It
has been known for a long time that JNK can be acti-
vated by exogenous ROS. Moreover, data from cell cul-
ture substantiates the notion that JNK activated by
oxidative stress jeopardizes cell survival as a pro-death
signal [29]. Li et al. reported that PRIMA-1MET induced
cell death through the JNK pathway in a p53-dependent
manner in colorectal cell lines [30]. Interestingly, we
found here that PRIMA-1MET induced JNK activation in
IB130 (mutated TP53) and IB139 (wild-type TP53)
indicating that this process was at least in part inde-
pendent of TP53. Moreover, JNK activation was not
present in STS cell lines for which PRIMA-1MET in-
duced autophagy. This may suggest that autophagy in-
duction and JNK activation may represent alternative
mechanism of STS cell death resulting from oxidative
stress induced by PRIMA-1MET. Our experimental con-
ditions applied on colon carcinoma cell lines equally
shown that cell death was not caspase dependent and
that PRIMA-1MET toxicity is not dependent of TP53 sta-
tus but largely involve oxidative stress.
Conclusion
In conclusion, our results confirm that the mechanisms
of action of PRIMA-1MET are more complex than firstly
described. We demonstrate here that PRIMA-1MET anti-
tumor activity in STS is P53-independent and results
mainly from off-target effects involving ROS-associated
toxicity without significant induction of caspase-
dependent-apoptosis. For this reason, PRIMA-1MET does
not deserve further development as a TP53-targeted
therapy in STS. However, further studies may be war-
ranted to assess potential synergy of PRIMA-1MET with
recognized active drugs in STS that interfere also with
the ROS pathway such as doxorubicin [31].
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